Skip to main content

Month: June 2020

Visteon to present at Deutsche Bank Global Auto Industry Conference on June 11

DETROIT, June 08, 2020 (GLOBE NEWSWIRE) — Visteon Corporation (Nasdaq: VC), a leading global supplier of vehicle cockpit electronics, will present at Deutsche Bank’s 2020 Global Auto Industry Conference on Thursday, June 11. Sachin Lawande, president and CEO, and Jerome Rouquet, senior vice president and chief financial officer, will present starting at approximately 8:30 a.m. ET and participate in a question-and-answer session. The presentation and Q&A session are expected to last approximately 35 minutes.A live audio webcast, along with the presentation material and other supplemental information, will be accessible through Visteon’s website at https://investors.visteon.com/events-presentations. A replay will be available following the event.About VisteonVisteon is a global technology company that designs, engineers and manufactures...

Continue reading

XP Inc. Acquires Stake in Fintech Fliper in Anticipation of the Ongoing Trend Toward Open Banking

SÃO PAULO, Brazil, June 08, 2020 (GLOBE NEWSWIRE) — XP Inc. (Nasdaq: XP), a leading, technology-driven financial services platform and a trusted provider of low-fee financial products and services in Brazil, announces the acquisition of a majority ownership stake in Fliper, an automated investment consolidation platform that offers its users connectivity and tools to perform intuitive and intelligent financial self-management. The transaction allows XP Inc. to offer its customers additional resources to manage their investments, as the open banking trend continues to accelerate in Brazil.The acquisition is part of XP Inc.’s growth strategy and reinforces the value that the company sees in innovative fintechs, constantly seeking to attract the best entrepreneurs to complement and improve its investment platform. Fliper’s founders...

Continue reading

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma

-PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic –-PBCAR269A is the First Off-the-Shelf Candidate Produced at In-House Manufacturing Center-DURHAM, N.C., June 08, 2020 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that the first patient has been dosed in a Phase 1/2a clinical trial of PBCAR269A, its third allogeneic chimeric antigen receptor (CAR) T cell therapy candidate. Wholly-owned by Precision, PBCAR269A targets the B-cell maturation antigen (BCMA) and is being evaluated for the treatment of relapsed/refractory multiple myeloma. “PBCAR269A...

Continue reading

Mesa Air Group Reports May 2020 Operating Performance

PHOENIX, June 08, 2020 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) today reported Mesa Airlines’ operating performance for May 2020.Mesa Airlines reported 12,077 block hours in May 2020, a 68.6 percent drop from May 2019 as a result of reduced schedules during the COVID-19 outbreak. The company also reported a controllable completion factor of 100 percent for both its American and United operations.Operating statistics for April 2020 and fiscal year 2020 YTD are included in the table below.*Controllable Completion Factor excludes cancellations due to weather and air traffic control**Total Completion Factor includes all cancellationsAbout Mesa Air Group, Inc.Headquartered in Phoenix, Arizona, Mesa Air Group, Inc. is the holding company of Mesa Airlines, a regional air carrier providing scheduled passenger service to 99...

Continue reading

Summit Appoints Michael Donaldson as Chief Financial Officer

Summit Therapeutics plc (‘Summit’ or the ‘Company’)Summit Appoints Michael Donaldson as Chief Financial OfficerOxford, UK, and Cambridge, MA, US, June 8, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Financial Officer, effective immediately. Mr. Donaldson brings to Summit over 20 years of finance experience, including the last nine years working in corporate finance.“Michael joins us at an exciting time in Summit’s growth with our ongoing Phase 3 clinical trials of our precision antibiotic candidate, ridinilazole, and the potential to bring a superior product to patients with C. difficile infection,” said Mr. Bob Duggan, Executive Chairman and Chief Executive Officer of Summit. “We welcome Michael’s expertise across a range of financial solutions for biotech companies...

Continue reading

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation of data from the Company’s Phase 1/2 trial of sepofarsen. The data will be shared via a video presentation through the Association for Research in Vision and Ophthalmology (ARVO). It is the first time this data, previously announced in a press release and conference call in October 2019, will be presented in association with an ophthalmology medical congress.Due to COVID-19, the ARVO 2020 Annual Meeting was cancelled and instead video-recorded presentations will be available on ARVOLearn, ARVO’s online learning platform.Details of ProQR’s presentation are...

Continue reading

Genco Shipping & Trading Leads the First Full Crew Change Under New COVID-19 Protocols in Singapore

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the transportation of major and minor bulk commodities globally, announced the successful full crew change of the Genco Liberty, a 180,032 DWT Capesize vessel, marking the first full crew change under new COVID-19 protocols in Singapore.  A total of 37 seafarers were involved in this crew change, which was completed on June 6, 2020 and executed in accordance with protocols established by Genco, Singapore’s Maritime and Port Authority (MPA) and the Synergy Group.John C. Wobensmith, Chief Executive Officer, commented, “Amid the outbreak of COVID-19, many individuals have been onboard oceangoing vessels in excess of the duration of their contracts, keeping...

Continue reading

Non-Small Cell Lung Cancer Therapeutics Market to reach US$ 43,713.1 Mn, Growing Adoption of Targeted Therapy for Diagnosis to Boost the Market, says Fortune Business Insights

Pune, June 08, 2020 (GLOBE NEWSWIRE) — The global non-small cell lung cancer therapeutics market is growing impressively due to recent surge in adoption of targeted therapy for treating non-small cell lung cancer. According to a report published by Fortune Business Insights, titled ‘Non-Small Cell Lung Cancer Therapeutics: Global Market Analysis, Insights and Forecasts, 2019-2026,’ the market value will rise substantially from US$ 16,011.7 Mn in 2018 to US$ 43,713.1 Mn by 2026.Fortune Business Insights has further predicted the market to exhibit an impressive CAGR of 13.4% between 2019 and 2026 due to exceptional advancements in targeted therapy in recent years. Such high growth can be attributable to the increasing demand for chemotherapy and targeted therapy. Furthermore, advantages of targeted therapy over other alternatives...

Continue reading

Monterey Minerals Announces Exploration Plans at Alicia Project in the Philippines

TORONTO, June 08, 2020 (GLOBE NEWSWIRE) — Monterey Minerals Inc. (the “Company” or “Monterey”) (CSE:MREY and FSE:2DK) is pleased to announce its 2020 exploration plans on the Alicia high-grade gold and base metals project in Alicia Municipality, Philippines (“Alicia Project”).  The exploration focus for the 2020 exploration plan will be to prove continuity between the previously identified veins and better understand the bigger system at depth that the Company’s technical team believes is feeding these near-surface veins along the greater than eleven (11) kilometers of strike.  2020 Exploration Plan Highlights:Exploration drilling along strike down to a depth of 300 metres to:Discover the source of the veins at surface and test the geologist’s premise that the vein systems are merging at depthDefine the down-dip continuity/extension...

Continue reading

CENTOGENE to Report First-Quarter 2020 Financial Results on June 15, 2020

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 08, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will issue a press release reporting its financial results for the three months ended March 31, 2020 on Monday, June 15, 2020, and will host a conference call to discuss these results at 8 a.m. EST that day.Participants may access the conference call on June 15, 2020 by dialing U.S. toll free +1 877 870 9135 or U.K. +44 (0) 800 279 6619 up to 10 minutes prior to the start of the call and by providing the conference ID number 4799325. The webcast of the conference call can and the related earnings presentation...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.